吉非贝齐与普伐他汀治疗冠状动脉疾病合并低高密度脂蛋白胆固醇水平患者的对比研究
[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].
作者信息
Santos R D, Mansur A P, Safi Júnior J, Giraldez R R, Maranhão R C, Pileggi F, Ramires J A
机构信息
Instituto do Coração do Hospital das Clínicas, FMUSP.
出版信息
Arq Bras Cardiol. 1995 Aug;65(2):181-3.
PURPOSE
To evaluate the effects of gemfibrozil and pravastatin in coronary artery disease patients with HDL-cholesterol (HDL-C) < 35 mg/dl).
METHODS
Twenty-nine patients (20 males, 60 +/- 9) were divided in a gemfibrozil group (G) (1200 mg/day n = 15) and a pravastatin group (P) (10 or 20 mg n = 10 and 4, respectively). The plasma lipid profile (LP) e.g. total cholesterol (TC), fractions and triglycerides (TG) was determined at 4 and 12 weeks of treatment.
RESULTS
HDL-C was not affected in P, TC and LDL-cholesterol (LDL-C) reductions were superior to those in G (31.3% vs 13.4% and 38.7 and 11.5%, p < 0.05 and < 0.01 respectively). In G HDL-C raised by 50% (12th week p < 0.01). Gemfibrozil reduced TG levels in 44.7% while in P it varied -32.2% (12th week p < 0.01 and < 0.05 respectively).
CONCLUSION
Gemfibrozil is more effective in reducing TG and raising HDL-C than pravastatin. On the other hand, pravastatin was more potent in reducing LDL-C levels.
目的
评估吉非贝齐和普伐他汀对高密度脂蛋白胆固醇（HDL-C）<35mg/dl的冠心病患者的影响。
方法
29例患者（20例男性，60±9岁）分为吉非贝齐组（G组）（1200mg/天，n = 15）和普伐他汀组（P组）（10mg或20mg，分别为n = 10和4）。在治疗4周和12周时测定血浆脂质谱（LP），例如总胆固醇（TC）、各组分和甘油三酯（TG）。
结果
P组中HDL-C未受影响，TC和低密度脂蛋白胆固醇（LDL-C）的降低优于G组（分别为31.3%对13.4%以及38.7%对11.5%，p分别<0.05和<0.01）。在G组中，HDL-C升高了50%（第12周，p<0.01）。吉非贝齐使TG水平降低44.7%，而在P组中变化为-32.2%（第12周，p分别<0.01和<0.05）。
结论
与普伐他汀相比，吉非贝齐在降低TG和升高HDL-C方面更有效。另一方面，普伐他汀在降低LDL-C水平方面更有效。
Zotero 插件